If you don't know your blood type, you're not alone. However it is important medical information to know, and here's how you ...

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...

Oxford, UK and San Jose, California, 9 January 2024 - (OBT), a clinical stage oncology company with a pipeline of ...

Alloy Therapeutics ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Five years after the first cases of COVID-19, reports of hMPV, an obscure respiratory virus in China may understandably raise ...

Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and Mitsubishi Tanabe with deals announced on the same day.

Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...

Women are less likely to receive a lung transplant than men and wait longer on the waiting list, but they have significantly ...

Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market ...

Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

Professor Jae-Byum Chang and Professor Yeon Sik Jung's joint research team of the Department of Materials Science and ...

Funding will propel Leyden Labs’ non-vaccine intranasal antibody programs to safeguard people from respiratory viruses. The ...